In a bat­tered field, As­traZeneca's lu­pus drug clears piv­otal study — but can they get it ap­proved now?

A year af­ter As­traZeneca ad­mit­ted de­feat in a late-stage study test­ing its lu­pus drug an­i­frol­um­ab, the British drug­mak­er has cleared their sec­ond piv­otal tri­al, hit­ting …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER